GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,870,000 shares, a growth of 30.5% from the February 13th total of 2,200,000 shares. Currently, 4.9% of the shares of the company are short sold. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is currently 2.0 days.
GlycoMimetics Price Performance
GLYC stock opened at $0.27 on Wednesday. GlycoMimetics has a twelve month low of $0.14 and a twelve month high of $3.18. The business’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.26.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last released its earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. As a group, equities research analysts expect that GlycoMimetics will post -0.08 EPS for the current fiscal year.
Institutional Investors Weigh In On GlycoMimetics
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on GlycoMimetics in a research note on Friday, March 14th. They issued a “sell” rating on the stock.
View Our Latest Stock Report on GlycoMimetics
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Read More
- Five stocks we like better than GlycoMimetics
- How to Use the MarketBeat Dividend Calculator
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Must-Own Stocks to Build Wealth This Decade
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.